Percheron Therapeutics Advances with Strong Funding and Trials
Company Announcements

Percheron Therapeutics Advances with Strong Funding and Trials

Percheron Therapeutics (AU:PER) has released an update.

Percheron Therapeutics has made significant progress in the past quarter, with its drug Avicursen showing promising preclinical results in reducing seizure frequency in autoimmune epilepsy. The company has also completed a crucial nine-month animal toxicology study with no unexpected findings and secured $13 million through an oversubscribed institutional placement, ensuring funding into 2026. Investors are eagerly anticipating the initial data readout from a Phase IIb trial of Avicursen in Duchenne muscular dystrophy, expected in December 2024.

For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPercheron Therapeutics Offers New Share Purchase Plan
TipRanks Australian Auto-Generated NewsdeskPercheron Therapeutics Lists New Securities on ASX
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App